Health in the City: Why Urbanisation can be a Risk Factor

Primary tabs

Health in the City: Why Urbanisation can be a Risk Factor

tweet me:
Cities influence how we live, travel and eat, all of which have an impact on our health. Read: http://bit.ly/1PHa07n via @novonordisktbl

Summary

Cities influence how we live, travel and eat, all of which have an impact on our health. Novo Nordisk’s latest issue of TBL Quarterly takes you to the city streets to show the challenges and opportunities to improve the health of urbanites living with type 2 diabetes. 

Thursday, March 31, 2016 - 9:10am

CAMPAIGN: The TBL Quarterly

CONTENT: Press Release

Denmark, March 31, 2016 /3BL Media/ - Today, Novo Nordisk published a new issue of the company’s sustainability magazine, TBL Quarterly. The latest instalment – The Urban Issue – presents recent research on urban health and some of the actions being taken to prevent chronic disease and improve treatment.  

Today, according to the International Diabetes Federation 2015 Diabetes Atlas, more than 400 million people are living with diabetes[1] and less than 10% achieve desired health outcomes.[2] With two thirds of people with diabetes living in urban areas, Novo Nordisk’s TBL Quarterly advocates for a new approach to address chronic disease. 

“Cities are where we can scale solutions and maximise impact for as many people as possible, and partnerships are needed for change to happen,” says Lars Rebien Sørensen, president and chief executive officer in Novo Nordisk. “This is why we launched our partnership programme Cities Changing Diabetes together with University College London and Steno Diabetes Center.”

From urban diets to daily commuting, The Urban Issue brings stories from the frontline of urban health and interviews with leading experts united to safeguard health in the city.

Download The Urban Issue  

The TBL Quarterly is published four times a year. If you want to receive a notification when new issues are available, please send an email to sustainability@novonordisk.com.
 

About the TBL Quarterly
Novo Nordisk manages its business in accordance with the Triple Bottom Line (TBL) business principle to ensure decisions reflect financial, social and environmental considerations. Through selected themes, new perspectives and personal stories, the TBL Quarterly shows what TBL looks like in practice and demonstrates how a TBL business principle supports long-term value creation. The TBL Quarterly is available as a reader-friendly PDF.

Explore previous issues of the TBL Quarterly

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions.

For more information, visit novonordisk.com/sustainability

 

[1] IDF. International Diabetes Federation. IDF Diabetes Atlas. 7th edn. Brussels, Belgium: International Diabetes Federation. 2015.

[2] Hart JT. Rule of Halves: implications of increasing diagnosis and reducing dropout for future workload and prescribing costs in primary care. Br J Gen Pract 1992; 42(356):116–119 and Smith WCS, Lee AJ, Crombie IK & Tunstall-Pedoe H. Control of blood pressure in Scotland: the rule of halves. BMJ 1990; 300:981–983

Contact

Charlotte Zarp-Andersson
+45-30797603
Keywords: Health & Healthcare | Innovation & Technology | Novo Nordisk | Responsible Business & Employee Engagement | Social Impact & Volunteering | TBL quarterly | diabetes

CAMPAIGN: The TBL Quarterly

CONTENT: Press Release

parse.ly